Overview

The landscape of diabetes treatment has shifted from a “one-size-fits-all” paradigm to one involving individualized care accounting for patient factors, preferences, and comorbidities. Participate in this 90-minute expert panel discussion to learn about the safety and efficacy of newer non-insulin therapies for type 2 diabetes, such as SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and their combinations. Faculty experts will answer crucial participant questions, explain considerations for selecting therapies based on guideline recommendations, and distill the latest clinical data for non-insulin T2DM management into concepts relevant to primary care.

Learning Objectives

  • Develop guideline-based treatment goals that best meet the individual needs of patients with diabetes and cardiometabolic issues. 
  • Distinguish among available and emerging diabetes therapies, used alone or in combination with other antihyperglycemic agents, with regard to efficacy and safety, in order to appropriately establish treatment regimens that best manage glycemic challenges, mitigate cardiometabolic risk, and achieve therapeutic goals. 
  • Apply current evidence and proven clinical strategies to reduce comorbid cardiovascular risks and complications of diabetes, including hypertension, dyslipidemia, coronary artery disease, and stroke  

Faculty Disclosures

Frank Lavernia, MD

Founder & Director
North Broward Diabetes Center
Pompano Beach, FL

Archana Sadhu, MD, FACE

Director, System Diabetes Program
Houston Methodist
Director, Transplant Endocrinology
Assistant Professor of Medicine
Weill Cornell Medical College
Adjunct Assistant Professor
Texas A&M Health Science Center
Houston, TX

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor,
UC Irvine Department of Family Medicine
Associate Dean for Diversity and Inclusion,
UC Irvine School of Medicine
Executive Director,
UC Irvine Program in Medical Education for the Latino Community
Irvine, CA

Disclosures

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

CME

AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement

pmiCME designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME

AANP

Accreditation Statement

pmiCME is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider number 040308. This activity was planned in accordance with AANP Accreditation Standards and Policies.


Designation Statement

This program has been approved for 1.50 contact hours of continuing education. Pharmacology credit is pending. 

Commercial Supporter

Sanofi US; Novo Nordisk Inc.; Merck & Co., Inc.; and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Education Partner

Not Applicable


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.